Shilpa Medicare Stock Soars After 11x Profit Surge and Institutional Stake Increase

Shilpa Medicare Ltd has emerged as a major winner in the stock market following its impressive financial performance for Q2 FY2025. The pharmaceutical company reported a staggering 11-fold increase in net profit, with post-tax profits (PAT) rising from ₹1.61 crore last year to ₹17.94 crore in the same quarter this year. This substantial growth has caught the attention of both Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII), who have significantly increased their stakes in the company.

Shilpa Medicare Sees Increased Institutional Investment

During the second quarter of FY2025, both FIIs and DIIs expanded their holdings in Shilpa Medicare. The FII’s stake increased from 9.08% in June 2024 to 9.59%, after acquiring an additional 4,90,977 shares. Meanwhile, DIIs increased their holding from 7.61% to 8.18% with the purchase of 5,63,162 shares.

This surge in institutional interest, coupled with the company’s exceptional quarterly results, has driven a 6% increase in Shilpa Medicare’s stock price, which closed at ₹871.55. The company’s financials show an impressive 9.8% increase in consolidated revenue, which rose to ₹343.8 crore from ₹312.98 crore last year. EBITDA saw a remarkable growth of 42.7%, reaching ₹86 crore, while the EBITDA margin improved to 25% from 19.3% in the same period last year.

Strong Returns and Solid Performance

Shilpa Medicare has also delivered impressive returns to its shareholders. The stock has generated a remarkable 72% return in the last six months alone, and its year-on-year growth stands at a staggering 164.78%. Over the past year, the stock price has surged by 135.57%, and the company’s market capitalization currently stands at ₹8,522.97 crore.

Given these strong financial results and the increasing institutional interest, Shilpa Medicare’s stock appears poised for further growth in the coming months.